FCRL5 and Miyoshi myopathy: FCRL5, a member of the immunoglobulin superfamily, is associated with B-cell ontogeny and lymphomagenesis,21 making it a promising target for antitumor therapies.20,38 Our serial analysis of FCRL5 expression in patients with MM, from primary tumors to relapse, substantiated its stable presence as a therapeutic target.